Within the biotech sector, the spinal cord injury (SCI) segment stands out as an enormous market with significant unmet needs. The World Health Organization estimates between 250,000 and 500,000 people around the world suffer from SCI each year. It’s also been estimated that around 291,000 people in the US currently
In 2021, Israeli businesses filed for a record number of IPOs on both U.S. and Israeli stock exchanges. Although IPOs are expected to be slower this year due to recent geopolitical and economic turbulence, the number of Israeli companies entering public markets remains extraordinary. Here are three companies we are
“ExoTherapy”, NurExone’s proprietary Exosome siRNA loaded product, is being developed to recover functionality in patients with traumatic spinal cord injuries read more
Hear from the CEO of NurExone Biologic Ltd, Israel’s promising new start-up which aims to utilize innovative Exosome-based technology and smart delivery platforms in order to revolutionize the way spinal cord injury (SCI) is treated around the world read more
In cooperation with two of Israel’s top universities, NurExone Biologic Ltd holds the potential to become one of the Start-Up Nation’s success, producing an exosome loaded drug-based platform to treat spinal cord and traumatic brain injuries. read more
Every year, around 500,000 people suffer from spinal cord acute injuries due to a variety of reasons, most commonly as a result of car accidents, work and sport accidents and more. The inability of the neuro cells in the Central Nerve System to regenerate leaves the majority of patients without
The demonstration that extracellular vesicles (EVs), carrying RNA, DNA, proteins, and lipids, play important roles in maintaining human health as well as contribute to driving disease has opened up a whole new field of research across all areas of biology, from development to host-pathogen interactions to tissue regeneration. read more
Bnei-Brak, Israel–(Newsfile Corp. – June 22, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (“NurExone” or the “Company“) is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it will commence trading on the TSX Venture Exchange (the “TSXV“) under
Calgary, Alberta–(Newsfile Corp. – June 15, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (the “Company“) is pleased to announce that it has completed its previously announced business combination transaction (the “Transaction“) with NurExone Biologic Ltd. (“NurExone“). read more
Calgary, Alberta–(Newsfile Corp. – May 17, 2022) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) and NurExone Biologic Ltd. (“NurExone“) are pleased to announce that the TSX Venture Exchange (“TSXV” or the “Exchange“) has conditionally accepted the previously announced reverse takeover transaction (the “RTO“) of EnerSpar pursuant to a
